GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE
Key facts
- Who runs it
- Imperial College London
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 36 people, planned
- Started
- 16 Apr 2025
- Planned end
- 31 Jul 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- FLUENZ
- Influenza challenge virus
- Record updated
- 20 April 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Adults aged between 18-55 years inclusive
- Sero-suitable as defined by a serum micro-neutralisation titre <1:20
- Female participant who is not of child-bearing potential as assessed by an investigator OR is willing and able to use contraception as described in the protocol
- Male participants who are willing to use one of the contraception methods described in the protocol
- In good health with no clinically significant medical conditions
Who cannot take part
- Inhaled bronchodilator/inhaled steroid use within the last 12 months before Day 0
- Receipt of systemic glucocorticoids (in a dose ≥ 5 mg prednisone daily or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within 6 months before Day 0
- Receipt of any vaccine within 30 days of Day -14
- Receipt of blood/blood products/loss (including blood donations) of 550 mL or more of blood during the 3 months prior to Day -14
- Significant history/presence of drug/alcohol misuse by self-report
- Current use of drugs through nose inhalation or inhaled route including recreational drugs
- Anyone with any of the following contraindications to receiving the Fluenz Tetra Vaccine:; Allergy to gentamicin, gelatin or the other ingredients of the fluenz vaccine
- History of clinically significant/currently active conditions;; Cardiovascular, thromboembolic/cerebrovascular disease; Types of chronic respiratory disease in adulthood; Significant wheeze in the past; Respiratory symptoms including wheeze, resulting in hospitalisation; Known bronchial hyperactivity to viruses; Diabetes mellitus; Migraine with associated symptoms like hemiplegia/vision loss. Cluster headache/migraine/prophylactic treatment for migraine; History of autoimmune disease/known immunodeficiency of any cause; Immunosuppression; Known coagulation disorder/anticoagulant therapy; Psychiatric illness including participants with a history of depression and/or anxiety with associated psychiatric comorbidities; Other major disease that, under the PI's discretion, could interfere with the participant completing the study
- Concurrent serious illness including history of malignancy that could interfere with the study or a participant completing the study
- Known IgA deficiency/immotile cilia syndrome/Kartagener's syndrome
- Significant abnormality altering the anatomy/function of the nose or nasopharynx, a clinically significant history of epistaxis within the last 3 months, nasal/sinus surgery within 6 months of Day 0, including nasopharyngeal malignancy, arterio-venous malformation, or undiagnosed nasopharyngeal mass
- Acute upper respiratory tract infection in the past 6 weeks
- Any significant medical condition/prescribed drug, under the PI's discretion
- History of anaphylaxis and/or a history of severe allergic reaction or significant intolerance to any food/drug, as assessed by the PI
- Clinically active rhinitis (including hay fever)/history of moderate to severe rhinitis/history of seasonal allergic rhinitis likely to be active at the time of inclusion into the study and/or requiring regular nasal corticosteroids on an at least weekly basis, within 30 days of enrolment
- Presence of cold-like symptoms and/or fever on Day -14 or Day 0
- Regular smoking and/or vaping and/or using nicotine-containing products in the past 3 months OR >5 pack-year lifetime history by self-report (5 pack years is equivalent to one pack of 20 cigarettes per day for 5 years)
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
This trial is currently available in United Kingdom.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This experimental medicine study aims to compare immune responses in healthy adult volunteers aged 18-55 years against influenza vaccination and infection in the upper and lower respiratory tract, following administration of a live-attenuated influenza vaccine delivered by nasal spray versus influenza A (H3N2) viral challenge.
The 2 groups in the trial
- LAIVTreatment being tested
Treatment: FLUENZ
- IAV ChallengeTreatment being tested
Treatment: Influenza challenge virus
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Two-arm, Non-randomised, Open-label Experimental Medicine Study to Compare Immune Responses Between Healthy Volunteers Aged 18-55years Receiving Either an Intranasal Live-attenuated Influenza Vaccine or Viral Challenge With GMP Influenza A/Belgium/4217/2015 (H3N2)
- Criteria questions
- Built from NCT06620185, who can take part
- Record updated
- 20 April 2026